

Engaging the patient community to ensure successful drug repurposing



Judit Baijet¹, Abby Stock-Duerdoth², Claudia Fuchs¹, Eve Hewitt², Virginie Hivert¹, William May², Rick Thompson²

1. EURORDIS- Rare Diseases Europe, Paris, France. 2. Beacon: for rare disease, Cambridge, UK.

PATIENT ENGAGEMENT IN REMEDI4ALL

Introduction

Drug repurposing interest is steadily increasing in a variety of areas such as policy, regulation, funding and research.

Although a huge amount of progress has been made in pushing forward this innovative opportunity in the drug development field, we frequently lack meaningful, efficient and effective patient-centric perspectives to address unmet medical needs.

Patients in a partnership role

REMEDi4ALL is positioning the **patient's voice and experience** at the heart of every repurposing project and empowering them as true **co-creators**.

To deliver on this mission, REMEDI4ALL is **embedding patient engagement** in all its four demonstrator projects as a core and essential principle for a patient-centric approach to drug repurposing.

-  **Patient Champion**
-  **Patient Advocacy Group**
-  **Patient Engagement Plan**
-  **Multi-stakeholder meetings**

PATIENT CHAMPIONS

A REMEDI4ALL patient champion has been defined as a **non-profit stakeholder developing or gathering evidence and expertise in order to accelerate the repurposing of a medicinal product for their target condition**. A champion may be a patient organisation representative, patient, carer, or advocate tied to collaborative groups such as umbrella charities or a European Reference Network (ERN).




Fig. 1 Patient champion characteristics

PATIENT ADVOCACY GROUP (PAG)

PAGs are set up to **provide the Patient Champion and Project Team with an additional source of patient insight** at key points within the project.

Their main purpose is to help all relevant parties access a more representative selection of patient experience as well as ensuring that the repurposed drug can **address the true need of the patient's community**.

PAGs are a **group of patients, relatives, carers or individual experts**, generally disease-specific, who **advocate for their community in different ways**; e.g., by providing training and education, participating in research projects, and by being involved in high-level discussions on treatment approvals with regulators and other stakeholders.




Fig. 2 Patient Advocacy Group governance and interactions

PATIENT ENGAGEMENT PLAN

The REMEDI4ALL Patient Engagement Plan is a living document developed to **help the project principal investigators and teams identify and implement patient engagement activities**.

This tool allows to ensure meaningful and continuous engagement throughout the project

This plan includes:

-  **Challenges related to patient engagement**
-  **Potential solutions to the identified challenges**
-  **Assessment of every step of the project**

MULTI-STAKEHOLDER MEETINGS

Multistakeholder meetings are regularly organised to **gather diverse stakeholders and tackle subjects relevant to the patient community**.


Patient centricity runs as the core narrative in all the multistakeholder meeting sessions ensuring that each stakeholder is considering the patient perspective in their current and future work.

Multi-stakeholder meetings aim at sharing information and advance learning, promoting dialogue and constructive interaction between all relevant stakeholders, and facilitating collaborations between all stakeholders.




Fig 3. Participants of the 1st REMEDI4ALL Multi-stakeholder meeting: Drug repurposing, an attractive strategy in pancreatic cancer treatment?


Patient Engagement Team





STAY TUNED FOR MORE!

 **Drug repurposing curriculum**

 **Podcast**

 **Mentoring program**

 **Webinar series**

 **Drug repurposing academy**

REMEDi4ALL website: <https://remedi4all.org/>
If you want to know more, please email us at: training@remedi4all.org